Page last updated: 2024-12-04

xanthosine 5'-triphosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

xanthosine 5'-phosphate : xanthosine phosphate compounds having phosphate groups at position 5'. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

5'-xanthylic acid : A purine ribonucleoside 5'-monophosphate having xanthine as the nucleobase. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

xanthosine 5'-triphosphate: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID73323
CHEMBL ID1206243
CHEBI ID15652
SCHEMBL ID188739
MeSH IDM0179666
PubMed CID439296
CHEMBL ID4443439
CHEBI ID10049
SCHEMBL ID625182
MeSH IDM0179666

Synonyms (54)

Synonym
CHEBI:15652 ,
xanthosine monophosphate
5'-xanthylic acid
xanthosine-5'-monophosphate
523-98-8
XANTHOSINE-5-PHOSPHATE ,
(9-d-ribosylxanthine)-5'-phosphate
xanthosine 5'-phosphate
xanthylic acid
C00655
1LOL
1PKX
1M9N
[(2r,3s,4r,5r)-5-(2,6-dioxo-3h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
CHEMBL1206243
((2s,3r,4s,5s)-5-(2,6-dihydroxy-9h-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl)methyl dihydrogen phosphate
SCHEMBL188739
5'-xanthonylate monophosphate
xanthosine-5'-phosphate
A848951
Q50362394
Q3132209
HYJ ,
9-[(2~{r},3~{r},4~{s},5~{r})-3,4-bis(oxidanyl)-5-[[tris(oxidanyl)-$l^{5}-phosphanyl]oxymethyl]oxolan-2-yl]-2-oxidanyl-1~{h}-purin-6-one
ammonium ((2r,3s,4r,5r)-5-(2,6-dihydroxy-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl phosphate
xanthosine 5'-monophosphate
DTXSID20966674
PD006971
(((2r,3s,4r,5r)-5-(2,6-dioxo-2,3,6,9-tetrahydro-1h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl)methoxy)phosphonic acid
xanthosine, mono(dihydrogen phosphate) (ester)
{[(2r,3s,4r,5r)-5-(2,6-dioxo-2,3,6,9-tetrahydro-1h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}phosphonic acid
EN300-7430402
6253-56-1
C00700
xanthosine 5'-triphosphate
xanthosine triphosphate
[[(2r,3s,4r,5r)-5-(2,6-dioxo-3h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
CHEBI:10049
o(5')-(tetrahydroxytriphosphoryl)xanthosine
triphopsphoric acid 1-xanthosin-5'-yl ester
SCHEMBL625182
({[({[(2r,3s,4r,5r)-5-(2,6-dihydroxy-9h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)phosphonic acid
xanthosine 5-triphosphate
xanthosine-5'-triphosphate
5'-xtp
xanthosine mono(tetrahydrogen triphosphate)
CZF ,
[[(2~{r},3~{s},4~{r},5~{r})-5-[2,6-bis(oxidanylidene)-3~{h}-purin-9-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl] phosphono hydrogen phosphate
Q3570564
DTXSID30978122
CHEMBL4443439
HY-115736
CS-0255072
AKOS040758244

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" IMPDH activity decreased to 75% and 67% at 1 and 2 h after dosing respectively."( Evaluation of inosin-5'-monophosphate dehydrogenase activity during maintenance therapy with tacrolimus.
Maiguma, T; Oishi, R; Okabe, Y; Otsubo, K; Sugitani, A; Tanaka, M; Teshima, D; Yosida, T, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
purine ribonucleoside 5'-monophosphate
xanthosine 5'-phosphatexanthosine phosphate compounds having phosphate groups at position 5'.
purine ribonucleoside 5'-triphosphate
xanthosine 5'-phosphatexanthosine phosphate compounds having phosphate groups at position 5'.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (39)

PathwayProteinsCompounds
Glutamate Metabolism2244
Purine Metabolism3766
4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency2244
Homocarnosinosis2244
Hyperinsulinism-Hyperammonemia Syndrome2244
Adenosine Deaminase Deficiency3766
Adenylosuccinate Lyase Deficiency3766
Gout or Kelley-Seegmiller Syndrome3766
Lesch-Nyhan Syndrome (LNS)3766
Molybdenum Cofactor Deficiency3766
Xanthine Dehydrogenase Deficiency (Xanthinuria)3766
Purine Nucleoside Phosphorylase Deficiency3766
AICA-Ribosiduria3766
2-Hydroxyglutric Aciduria (D and L Form)2244
Azathioprine Action Pathway4782
Mercaptopurine Action Pathway4780
Thioguanine Action Pathway4781
Xanthinuria Type I3766
Xanthinuria Type II3766
Adenine Phosphoribosyltransferase Deficiency (APRT)3766
Mitochondrial DNA Depletion Syndrome-33766
Myoadenylate Deaminase Deficiency3766
Succinic Semialdehyde Dehydrogenase Deficiency2244
Purine Nucleotides De Novo Biosynthesis2945
Purine Nucleotides De Novo Biosynthesis 22945
Purine Ribonucleosides Degradation717
Mitochondrial DNA Depletion Syndrome3566
Purine nucleotides and Nucleosides metabolism ( Purine nucleotides and Nucleosides metabolism )10577
XMP + Pyrophosphate = Xanthine + D-5-Phospho-ribosyl 1-diphosphate ( Purine nucleotides and Nucleosides metabolism )14
The impact of Nsp14 on metabolism (COVID-19 Disease Map)084
salvage pathways of purine nucleosides021
purine nucleotide metabolism (phosphotransfer and nucleotide modification)023
purine nucleotides de novo biosynthesis I039
superpathway of histidine, purine, and pyrimidine biosynthesis064
purine nucleotides de novo biosynthesis II033
salvage pathways of guanine, xanthine, and their nucleosides017
salvage pathways of purine nucleosides I027
Ureide biosynthesis017
Biochemical pathways: part I0466

Protein Targets (10)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, orotidine 5'-monophosphate decarboxylaseMethanothermobacter thermautotrophicus str. Delta HKi0.41000.000050.1185200.0000AID977610
Chain B, orotidine 5'-monophosphate decarboxylaseMethanothermobacter thermautotrophicus str. Delta HKi0.41000.000050.1185200.0000AID977610
Chain A, orotidine 5'-monophosphate decarboxylaseArchaeaKi0.41000.000050.1185200.0000AID977610
Chain A, orotidine monophosphate decarboxylaseMethanothermobacter thermautotrophicusKi0.41000.000050.1185200.0000AID977610
Chain A, orotidine monophosphate decarboxylaseMethanothermobacter thermautotrophicus str. Delta HKi0.41000.000050.1185200.0000AID977610
Chain B, orotidine monophosphate decarboxylaseMethanothermobacter thermautotrophicus str. Delta HKi0.41000.000050.1185200.0000AID977610
Chain A, Aicar Transformylase-imp CyclohydrolaseGallus gallus (chicken)Ki0.12000.12000.12000.1200AID977610
Chain B, Aicar Transformylase-imp CyclohydrolaseGallus gallus (chicken)Ki0.12000.12000.12000.1200AID977610
Chain A, Bifunctional purine biosynthesis protein PURHHomo sapiens (human)Ki0.12000.12000.12000.1200AID977610
Chain B, Bifunctional purine biosynthesis protein PURHHomo sapiens (human)Ki0.12000.12000.12000.1200AID977610
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID1811Experimentally measured binding affinity data derived from PDB2002Biochemistry, Dec-31, Volume: 41, Issue:52
Structural insights into the avian AICAR transformylase mechanism.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2002Biochemistry, Dec-31, Volume: 41, Issue:52
Structural insights into the avian AICAR transformylase mechanism.
AID1811Experimentally measured binding affinity data derived from PDB2002The Journal of biological chemistry, Aug-02, Volume: 277, Issue:31
Crystal structures of inhibitor complexes reveal an alternate binding mode in orotidine-5'-monophosphate decarboxylase.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2002The Journal of biological chemistry, Aug-02, Volume: 277, Issue:31
Crystal structures of inhibitor complexes reveal an alternate binding mode in orotidine-5'-monophosphate decarboxylase.
AID1811Experimentally measured binding affinity data derived from PDB2004Biochemistry, Feb-10, Volume: 43, Issue:5
Structural insights into the human and avian IMP cyclohydrolase mechanism via crystal structures with the bound XMP inhibitor.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2004Biochemistry, Feb-10, Volume: 43, Issue:5
Structural insights into the human and avian IMP cyclohydrolase mechanism via crystal structures with the bound XMP inhibitor.
AID1541392Substrate activity at recombinant full-length mouse CGAS expressed in Escherichia coli BL21 (DE3) assessed as cyclic dinucleotide formation by measuring reaction conversion at 1 mM incubated for 16 hrs in presence of ATP by HPLC-UV analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1541389Substrate activity at recombinant full-length mouse CGAS expressed in Escherichia coli BL21 (DE3) assessed as cyclic dinucleotide formation by measuring reaction conversion at 1 mM incubated for 16 hrs in presence of GTP by HPLC-UV analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1541390Substrate activity at recombinant full-length chicken CGAS expressed in Escherichia coli BL21 (DE3) assessed as cyclic dinucleotide formation by measuring reaction conversion at 1 mM incubated for 16 hrs in presence of GTP by HPLC-UV analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1541388Substrate activity at recombinant full-length human CGAS expressed in Escherichia coli BL21 (DE3) assessed as cyclic dinucleotide formation by measuring reaction conversion at 1 mM incubated for 16 hrs in presence of GTP by HPLC-UV analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1541393Substrate activity at recombinant full-length chicken CGAS expressed in Escherichia coli BL21 (DE3) assessed as cyclic dinucleotide formation by measuring reaction conversion at 1 mM incubated for 16 hrs in presence of ATP by HPLC-UV analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1541391Substrate activity at recombinant full-length human CGAS expressed in Escherichia coli BL21 (DE3) assessed as cyclic dinucleotide formation by measuring reaction conversion at 1 mM incubated for 16 hrs in presence of ATP by HPLC-UV analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (95)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (15.79)18.7374
1990's34 (35.79)18.2507
2000's28 (29.47)29.6817
2010's16 (16.84)24.3611
2020's2 (2.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.64%)5.53%
Trials0 (0.00%)5.53%
Reviews1 (1.64%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational1 (1.64%)0.25%
Observational0 (0.00%)0.25%
Other58 (95.08%)84.16%
Other38 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]